

Academic Personnel Short Profile / Short CV

University:	University of Nicosia
Surname:	Galazi
Name:	Myria
Rank/Position:	Clinical Assistant Professor
Faculty:	Medical School
Department:	Basic and Clinical Sciences
Scientific Domain:	Medical Oncology

Academic qualifications

Qualification	Year	Awarding Institution	Department	Thesis title (Optional Entry)
Certificate of Completion of training in Medical Oncology	2021	Joint Royal Colleges of Physicians Training Board (JRCPTB)		
PhD	2019	University College London	Molecular Oncology	ErbB activation and heterodimerisation is responsible for resistance upon PI3K-mTOR inhibition in metastatic prostate cancer
MBBS Medicine	2009	University College London		
Intercalated BSc	2006	University College London	Physiology	

Employment history in Academic Institutions/Research Centers

Period of employment		Employer	Location	Position
From	To			
2022	Present	University of Nicosia	Nicosia, Cyprus	Clinical Associate

2015	2018	University College London	London, UK	Clinical Research Fellow
------	------	---------------------------	------------	--------------------------

Key refereed journal papers, monographs, books, conference publications etc.						
Ref. Number	Year	Title	Other authors	Journal and Publisher / Conference	Vol.	Pages
1	2021	Systemic Anti-Cancer Therapy and Metastatic Cancer Are Independent Mortality Risk Factors during Two UK Waves of the COVID-19 Pandemic at University College London Hospital.	Wong YNS, Sng CCT, Ottaviani D, Patel G, Chowdhury A, Earnshaw I, Sinclair A, Merry E, Wu A, Galazi M , Benafif S, Soosaipillai G, Chopra N, Roylance R, Shaw H, Lee AJX.	Cancers (Basel)		
2	2021	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry.	Garrigós L, Saura C, Martinez-Vila C, Zambelli A, Bower M, Pistilli B, Lambertini M, Ottaviani D, Diamantis N, Lumsden A, Pernas S, Generali D, Seguí E, Viñas G, Felip E, Sanchez A, Rizzo G, Santoro A, Cortellini A, Perone Y, Chester J, Iglesias M, Betti M, Vincenzi B, Libertini M, Mazzoni F, Zoratto F, Berardi R, Guida A, Wuerstlein R, Loizidou A, Sharkey R, Aguilar Company J, Matas M, Saggia C,	Ther Adv Med Oncol		

			Chiudinelli L, Colomba-Blameble E, Galazi M , Mukherjee U, Van Hemelrijck M, Marin M, Strina C, Prat A, Pla H, Ciruelos EM, Bertuzzi A, Del Mastro L, Porzio G, Newsom-Davis T, Ruiz I, Delany MB, Krengli M, Fotia V, Viansone A, Chopra N, Romeo M, Salazar R, Perez I, d'Avanzo F, Franchi M, Milani M, Pommeret F, Tucci M, Pedrazzoli P, Harbeck N, Ferrante D, Pinato DJ, Gennari A.			
3	2021	<u>Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study.</u>	Pinato DJ, Tabernero J, Bower M, Scotti L, Patel M, Colomba E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Dalla Pria A, Aguilar-Company J, Ottaviani D, Chowdhury A, Merry E, Salazar R, Bertuzzi A, Brunet J, Lambertini M, Tagliamento M, Pous A, Sita-Lumsden A, Srikandarajah K, Colomba J, Pommeret F, Seguí E, Generali D, Grisanti S, Pedrazzoli P, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Harbeck N, Vincenzi B, Biello F, Bertulli R, Liñan R, Rossi S, Carmona-García MC, Tondini C, Fox L, Baggi A, Fotia V, Parisi A,	Lancet Oncol		

			Porzio G, Saponara M, Cruz CA, García-Illescas D, Felip E, Roqué Lloveras A, Sharkey R, Roldán E, Reyes R, Earnshaw I, Ferrante D, Marco-Hernández J, Ruiz-Camps I, Gaidano G, Patriarca A, Bruna R, Sureda A, Martinez-Vila C, Sanchez de Torre A, Cantini L, Filetti M, Rimassa L, Chiudinelli L, Franchi M, Krengli M, Santoro A, Prat A, Van Hemelrijck M, Diamantis N, Newsom-Davis T, Gennari A, Cortellini A; OnCovid study group.			
4	2021	<u>Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective.</u>	Soosaipillai G, Wu A, Dettorre GM, Diamantis N, Chester J, Moss C, Aguilar-Company J, Bower M, Sng CC, Salazar R, Brunet J, Jones E, Mesia R, Jackson A, Mukherjee U, Sita-Lumsden A, Seguí E, Ottaviani D, Carbó A, Benafif S, Würstlein R, Carmona C, Chopra N, Cruz CA, Swallow J, Saoudi N, Felip E, Galazi M , Garcia-Fructuoso I, Lee AJX, Newsom-Davis T, Wong YNS, Sureda A, Maluquer C, Ruiz-Camps I, Cabirta A, Prat A, Loizidou A, Gennari A, Ferrante D, Tabernero J, Russell B, Van Hemelrijck M,	Ther Adv Med Oncol		

			Dolly S, Hulbert-Williams NJ, Pinato DJ.			
5	2021	<u>Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study.</u>	Pinato DJ, Scotti L, Gennari A, Colomba-Blameble E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Aguilar-Company J, Bower M, Galazi M , Salazar R, Bertuzzi A, Brunet J, Mesia R, Sita-Lumsden A, Colomba J, Pommeret F, Seguí E, Biello F, Generali D, Grisanti S, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Wuerstlein R, Vincenzi B, Bertulli R, Ottaviani D, Liñan R, Marrari A, Carmona-García MC, Sng CCT, Tondini C, Mirallas O, Tovazzi V, Fotia V, Cruz CA, Saoudi-Gonzalez N, Felip E, R Lloveras A, Lee AJX, Newsom-Davis T, Sharkey R, Chung C, García-Illescas D, Reyes R, Sophia Wong YN, Ferrante D, Marco-Hernández J, Ruiz-Camps I, Gaidano G, Patriarca A, Sureda A, Martinez-Vila C, Sanchez de Torre A, Rimassa L, Chiudinelli L, Franchi M, Krenqli M, Santoro A, Prat A, Tabernero J, V Hemelrijck M, Diamantis N, Cortellini A; OnCovid study group.	Eur J Cancer		

--	--	--	--	--	--

Exhibitions					
Ref. Number	Date	Topic	International / Local	Location*	Role in Exhibition
1	2020	Do cancer patients really do worse? A study in a UK tertiary hospital within a COVID-19 epicenter	International	ESMO	
2	2020	Provision of palliative care for patients with cancer and Sars-CoV-2 Infection	International	ESMO	
3	2020	COVID-19 mortality in patients receiving anti-cancer therapy in a UK national cancer centre	International	ESMO	
4	2019	ASCO 2019 Breast cancer highlights and patient case forum	Local	Royal College of Physicians	
5	2018	Targeted prostate cancer biomarkers	Local	King's College London	
6	2018	Effect of HER3 dimer feedback upregulation via PI3K-AKT-mtor pathway inhibition on androgen receptor (AR) stabilisation in metastatic prostate cancer	International	GU ASCO	
7	2018	HER3 dimer feedback upregulation via PI3K-AKT-mTOR pathway inhibition leads to androgen receptor (AR) stabilisation in metastatic prostate cancer	International	EAU18	
8	2017	Circulating biomarkers; exploiting exosomes	Local	King's College London	
9	2016	HER3 targeting in castration resistant prostate cancer	Local	King's College London	
10	2015	Immunomodulation of myeloid-derived suppressor cell subpopulations by non-small cell lung carcinoma derived	National	CRUK Lung Cancer Conference	

		exosomes			
--	--	----------	--	--	--

Research Projects				
Ref. Number	Date	Title	Funded by	Project Role*
1	2015-2018	ErbB activation and heterodimerisation is responsible for resistance upon PI3K-mTOR inhibition in metastatic prostate cancer	CRUK	Clinical Research Fellow/PhD Student